Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $31.00

Trevi Therapeutics (NASDAQ:TRVI) had its price target upped by B. Riley Financial from $21.00 to $31.00 in a research note published on Monday, MarketBeat reports. They currently have a buy rating on the stock.

Other research analysts have also recently issued reports about the stock. Stifel Nicolaus set a $30.00 target price on shares of Trevi Therapeutics in a report on Friday, May 8th. Morgan Stanley reaffirmed an “overweight” rating and set a $20.00 price target on shares of Trevi Therapeutics in a report on Wednesday, May 6th. D. Boral Capital restated a “buy” rating and set a $19.00 price objective on shares of Trevi Therapeutics in a research report on Friday, April 17th. Wall Street Zen upgraded shares of Trevi Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $24.91.

Trevi Therapeutics Stock Performance

Shares of TRVI stock opened at $17.36 on Monday. Trevi Therapeutics has a 52-week low of $6.55 and a 52-week high of $20.22. The stock has a market cap of $2.46 billion, a price-to-earnings ratio of -54.25 and a beta of 1.00. The firm’s 50-day moving average is $16.00 and its 200-day moving average is $13.43.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). Sell-side analysts predict that Trevi Therapeutics will post -0.47 EPS for the current fiscal year.

Institutional Trading of Trevi Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TRVI. Hilton Head Capital Partners LLC boosted its stake in Trevi Therapeutics by 32.6% in the 1st quarter. Hilton Head Capital Partners LLC now owns 4,250 shares of the company’s stock worth $51,000 after purchasing an additional 1,044 shares during the period. AlphaCentric Advisors LLC grew its holdings in Trevi Therapeutics by 5.7% during the 1st quarter. AlphaCentric Advisors LLC now owns 23,970 shares of the company’s stock valued at $286,000 after buying an additional 1,303 shares in the last quarter. Kennedy Capital Management LLC increased its position in shares of Trevi Therapeutics by 2.4% during the fourth quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company’s stock valued at $704,000 after buying an additional 1,336 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Trevi Therapeutics by 32.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock valued at $78,000 after buying an additional 1,523 shares during the period. Finally, Oppenheimer & Co. Inc. lifted its holdings in shares of Trevi Therapeutics by 2.1% in the fourth quarter. Oppenheimer & Co. Inc. now owns 100,698 shares of the company’s stock worth $1,261,000 after buying an additional 2,030 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.